Bevasiranib
Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF) . It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD) .
Product Specifications
CAS Number
959961-96-7
UNSPSC
12352208
Target
Small Interfering RNA (siRNA) ; VEGFR
Type
Oligonucleotides
Related Pathways
Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/bevasiranib.html
Solubility
10 mM in H2O
Smiles
[Bevasiranib]
Molecular Formula
C401H503N153O290P40
Molecular Weight
13345.07
References & Citations
[1]Garba AO, Mousa SA. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis. 2010;2:75-83.|[2]Dejneka NS, Wan S, Bond OS, Kornbrust DJ, Reich SJ. Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis. 2008;14:997-1005.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Phase 3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
